On those newsletter catalysts, it would seem to me that points 13, 14 and 15 could all be lumped together as one catalyst. These were respectively Website launch, E-shop launch and global Cyacelle launch. I would really like to see something about NICE, there has been lots of bluster from the company about legal action but still nothing as far as I know. The rough situation I believe is Scenesse is approved in England for EPP but NICE rejected it for funding and CUV and the IPF then won two appeals against NICE but still nothing has changed for EPP patients. In my opinion it would have been better for EPP patients, shareholders and everyone if Clinuvel had just given some token discount many years ago and moved on as NICE is very average in looking after their own constituents. Hopefully something changes for those long suffering EPP patients this year.
All IMO DYOR
On those newsletter catalysts, it would seem to me that points...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.39 |
Change
-0.410(2.77%) |
Mkt cap ! $720.6M | |||
| Open | High | Low | Value | Volume |
| $14.95 | $14.97 | $14.39 | $3.585M | 247.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1875 | $14.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.61 | 129 | 1 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |